Domínguez-Jurado, E.; Cimas, F.J.; Castro-Osma, J.A.; Juan, A.; Lara-Sánchez, A.; Rodríguez-Diéguez, A.; Shafir, A.; Ocaña, A.; Alonso-Moreno, C.
Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics 2021, 13, 1559.
https://doi.org/10.3390/pharmaceutics13101559
AMA Style
Domínguez-Jurado E, Cimas FJ, Castro-Osma JA, Juan A, Lara-Sánchez A, Rodríguez-Diéguez A, Shafir A, Ocaña A, Alonso-Moreno C.
Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics. 2021; 13(10):1559.
https://doi.org/10.3390/pharmaceutics13101559
Chicago/Turabian Style
Domínguez-Jurado, Elena, Francisco J. Cimas, José Antonio Castro-Osma, Alberto Juan, Agustín Lara-Sánchez, Antonio Rodríguez-Diéguez, Alexandr Shafir, Alberto Ocaña, and Carlos Alonso-Moreno.
2021. "Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer" Pharmaceutics 13, no. 10: 1559.
https://doi.org/10.3390/pharmaceutics13101559
APA Style
Domínguez-Jurado, E., Cimas, F. J., Castro-Osma, J. A., Juan, A., Lara-Sánchez, A., Rodríguez-Diéguez, A., Shafir, A., Ocaña, A., & Alonso-Moreno, C.
(2021). Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics, 13(10), 1559.
https://doi.org/10.3390/pharmaceutics13101559